The European Medicines Agency extends indications for lapatinib

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product lapatinib (Tyverb). Lapatinib is indicated for the treatment of adult patients with breast cancer whose tumours overexpress HER2 (ErbB2) in combination with capecitabine or an aromatase inhibitor. The CHMP has now recommended it for the treatment in combination with trastuzumab. Read more here.